POLB.L
Price:
$2.7
Market Cap:
$13.50M
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker plat...[Read more]
Industry
Biotechnology
IPO Date
2021-07-19
Stock Exchange
LSE
Ticker
POLB.L
According to Poolbeg Pharma PLC’s latest financial reports and current stock price. The company's current ROE is -32.56%. This represents a change of 115.07% compared to the average of -15.14% of the last 4 quarters.
The mean historical ROE of Poolbeg Pharma PLC over the last ten years is -21.05%. The current -32.56% ROE has changed 54.71% with respect to the historical average. Over the past ten years (40 quarters), POLB.L's ROE was at its highest in in the December 2021 quarter at 0%. The ROE was at its lowest in in the June 2024 quarter at -18.14%.
Average
-21.05%
Median
-25.57%
Minimum
-27.22%
Maximum
-10.35%
Discovering the peaks and valleys of Poolbeg Pharma PLC ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 147.20%
Maximum Annual ROE = -10.35%
Minimum Annual Increase = 0%
Minimum Annual ROE = -27.22%
Year | ROE | Change |
---|---|---|
2023 | -27.22% | 6.43% |
2022 | -25.57% | 147.20% |
The current ROE of Poolbeg Pharma PLC (POLB.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-21.05%
5-year avg
-21.05%
10-year avg
-21.05%
Poolbeg Pharma PLC’s ROE is less than hVIVO plc (47.93%), greater than Polarean Imaging plc (-86.11%), greater than DeepVerge plc (-13.78%), greater than Avacta Group Plc (-74.00%), greater than Shield Therapeutics plc (-470.50%),
Company | ROE | Market cap |
---|---|---|
47.93% | $103.02M | |
-86.11% | $12.37M | |
-13.78% | $1.16M | |
-74.00% | $141.66M | |
-470.50% | $29.17M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Poolbeg Pharma PLC using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Poolbeg Pharma PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Poolbeg Pharma PLC's ROE?
How is the ROE calculated for Poolbeg Pharma PLC (POLB.L)?
What is the highest ROE for Poolbeg Pharma PLC (POLB.L)?
What is the 3-year average ROE for Poolbeg Pharma PLC (POLB.L)?
What is the 5-year average ROE for Poolbeg Pharma PLC (POLB.L)?
How does the current ROE for Poolbeg Pharma PLC (POLB.L) compare to its historical average?